A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
RecruitingPhase 1
A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
Who can join
Ages 18 to 55 · Women
Full eligibility criteria
Inclusion Criteria: * Male or female, 18-55 years. * BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea. * Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days. * Able to comply with study procedures and reproductive requirements. Exclusion Criteria: * Diabetes or obesity due to endocrine/genetic causes. * Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment. * Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks. * Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia. * Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.
About the study
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
What is being tested
- CX11 (drug)
- Placebo (other)
- CX11 (drug)
Sponsor: Corxel Pharmaceuticals · Participants: 90 · Started: May 11, 2026
Contact the study team
- Study coordinator · Phone: 201-268-3723
Official record on ClinicalTrials.gov — NCT07652047
Locations in the U.S.
| Nevada | Corxel Investigational site, Las Vegas |
| Texas | Corxel Investigational Site, Austin |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.